Pages that link to "Q56588945"
Jump to navigation
Jump to search
The following pages link to Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis (Q56588945):
Displaying 50 items.
- Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis (Q26828463) (← links)
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer (Q26829939) (← links)
- Is blood pressure reduction a valid surrogate endpoint for stroke prevention? [etc.] (Q27028633) (← links)
- Bevacizumab treatment for advanced breast cancer (Q27027498) (← links)
- EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer (Q27851583) (← links)
- EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis (Q27852970) (← links)
- The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis (Q28070325) (← links)
- Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol (Q28652334) (← links)
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma (Q30437854) (← links)
- Time-dependent endpoints as predictors of overall survival in multiple myeloma (Q30538040) (← links)
- Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy (Q30833179) (← links)
- Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists (Q33600372) (← links)
- Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study (Q33733088) (← links)
- Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene (Q33933021) (← links)
- Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study (Q34567058) (← links)
- Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study (Q34579641) (← links)
- A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer (Q34603889) (← links)
- Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer (Q34866341) (← links)
- Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed (Q36070007) (← links)
- Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology (Q36349459) (← links)
- Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy (Q36490413) (← links)
- Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials (Q36730313) (← links)
- The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat (Q36966415) (← links)
- Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer (Q36977501) (← links)
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer (Q37274280) (← links)
- Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint (Q37292020) (← links)
- Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis (Q37312451) (← links)
- Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer (Q37389608) (← links)
- Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma (Q37405933) (← links)
- Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy (Q37584918) (← links)
- Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer (Q37901096) (← links)
- Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer (Q37955095) (← links)
- Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer (Q38026294) (← links)
- Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review (Q38233353) (← links)
- Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. (Q38259501) (← links)
- Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? (Q38389980) (← links)
- Clinical significance of post-progression survival in lung cancer (Q38669447) (← links)
- Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials (Q38720644) (← links)
- Surrogate endpoints for overall survival in lung cancer trials: a review (Q38841987) (← links)
- Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer (Q38843828) (← links)
- Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy (Q38852314) (← links)
- Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies (Q38948814) (← links)
- Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide (Q39572955) (← links)
- Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials (Q39778923) (← links)
- Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer (Q39831851) (← links)
- Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? (Q40025547) (← links)
- Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma (Q41898172) (← links)
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial (Q42940352) (← links)
- Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer (Q43518078) (← links)
- FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). (Q43649036) (← links)